Cash-Secured PutNVO · USRisk: Low

Cash-Secured Put on Novo Nordisk A/S

Complete example: Cash-Secured Put on Novo Nordisk (NVO) — including strikes, premium, break-even, and interactive payoff diagram.

Market view

Neutral to mildly bullish

Complexity

Beginner

Sector

Consumer

Typical price

$85,00

Underlying

Novo Nordisk A/S for Options Traders

Novo Nordisk A/S is the Danish pharma giant behind the GLP-1 blockbusters Ozempic and Wegovy, and one of Europe's most valuable companies. US options are accessible via its NYSE-listed ADRs (ticker NVO). News on trials, competition (Eli Lilly) and manufacturing capacity pushes volatility to an elevated level (IV 30-52%) — attractive for premium strategies with clearly defined risk.

Symbol

NVO

Market

IV range

30–52%

Currency

USD

Options note: US ADR options (NYSE); American-style; weekly expirations; solid liquidity for a European pharma name.

Overview

Cash-Secured Put — Quick Overview

In a cash-secured put, you sell a put option on a stock you'd like to own at a lower price. You keep enough cash on hand to buy the shares if necessary. The option premium is credited to your account immediately. If the option is exercised, you buy the shares at the strike — effectively at a lower price than today (strike minus premium). If it expires worthless, you simply keep the premium.

Advantages

Immediate premium income regardless of price direction
Automatically better entry price if assigned (strike − premium)
Simple to understand and implement
Lower risk than direct stock purchase (premium cushions losses)

Disadvantages

Capital is tied up for the duration of the trade (opportunity cost)
Miss out on price increases above current price (no upside exposure)
Full stock loss possible if price falls sharply after assignment
Assignment in a sharp downturn undesirable if you no longer want to own the stock

Full Cash-Secured Put Guide

Example Trade

Cash-Secured Put on Novo Nordisk

Illustrative example based on a typical Novo Nordisk price of $85,00. Strikes and premiums are indicative — actual market prices will vary.

Position	Type	Strike	Action	Premium
Short Put (sold)	Put	$80,00	Sell (credit)	+$1,70
Net credit received				+$1,70 ($170 per contract)

Max Profit

$170

per contract

Max Loss

-$7.830

per contract

Break-even

$78,30

Payoff

Payoff Diagram at Expiration

Profit and loss of the Cash-Secured Put on Novo Nordisk depending on the price at expiration. Values per contract (100 shares).

Suitability

Why Cash-Secured Put for Novo Nordisk?

Medium volatility offers sufficient premiums for regular cash-secured puts (1.5-2.5% monthly). Timing is more important for more volatile underlyings: open puts preferably after a price decline (elevated IV) and close at 50-75% profit. Pay particular attention to quarterly earnings and close positions before earnings.

When is the right time?

1The stock would be attractive to you at a 5-10% lower price
2IV Rank elevated (above 30%) for better premiums
3Sufficient capital available (strike × 100 shares)
4No upcoming earnings event within the term (or intentionally timed around it)
5Underlying fundamentally attractive — you genuinely want to own it if assigned

Deep Dive

Why Novo Nordisk for Options Traders

Novo Nordisk is one of Europe's most valuable companies and the market leader in GLP-1 drugs (Ozempic, Wegovy). Liquid US options are accessible via its NYSE-listed ADRs (ticker NVO). IV is elevated at typically 30-52%, driven by trial data, competition (Eli Lilly) and manufacturing capacity. For options traders NVO is an underlying with solid premiums and a clear fundamental story — suitable for defined-risk premium strategies.

Strategy Notes

Cash-Secured Put on Novo Nordisk: Practical Notes

Cash-secured puts are a good way to acquire NVO more cheaply after a pullback — sensible because the stock historically falls sharply but often only temporarily. The elevated IV pays attractive premiums. The key check is whether you believe in the long-term GLP-1 story; if so, a possible assignment price below the current level is an acceptable outcome.

Historical Context

Novo Nordisk saw an exceptional re-rating in 2021-2023 as Ozempic and Wegovy opened up the obesity market. Sharp pullbacks followed as disappointing trial data (including on next-generation drugs) and growing competitive pressure from Eli Lilly weighed on the valuation. These swings between euphoria and disappointment produce recurring IV spikes around trial results and quarterly reports. Traders should keep the calendar of clinical data and approval decisions in view.

FAQ

FAQ: Cash-Secured Put on Novo Nordisk

How do I trade Novo Nordisk options as a German investor?

The most liquid route is US options on the NYSE ADRs (ticker NVO), which requires a broker with access to US options markets. These options are American-style with weekly expirations. Alternatively, European derivatives venues list options on the Danish ordinary share, but with lower liquidity. This content is informational, not investment advice.

What drives volatility on Novo Nordisk?

The most important driver is clinical trial data on GLP-1 drugs and their successors, followed by competition with Eli Lilly and manufacturing-capacity news. Both positive and negative surprises often move the stock by double digits. IV rises materially around these dates and collapses afterward — a classic pattern to account for when timing options strategies.

Is NVO suitable for conservative income strategies?

Relatively well, compared with high-volatility momentum names. The elevated but not extreme IV (30-52%) and the fundamental market leadership make covered calls and cash-secured puts sensible. It nonetheless remains a single stock with clinical risk — limit position size and avoid trial/earnings dates. This content is informational only.